Corvus Pharmaceuticals price target raised to $14 from $8 at Oppenheimer
The Fly

Corvus Pharmaceuticals price target raised to $14 from $8 at Oppenheimer

Oppenheimer analyst Jeff Jones raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $14 from $8 and keeps an Outperform rating on the shares following quarterly results. The firm is highly encouraged by management’s enthusiasm for the upcoming atopic dermatitis readout in December. Cash remains constrained given the level of clinical activity, with Q3-ending cash reported at $42M, providing runway into early 2026, by Oppenheimer’s estimate.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App